Our Areas of Focus
We focus on innovation with the greatest potential to help patients with high unmet medical needs in bone and mineral diseases, intractable haematological diseases and haemato-oncology, and rare disease.
Bone and Mineral Diseases
Many bone and mineral diseases remain underdiagnosed, with a lack of treatment often leading to problems with growth and development. At Kyowa Kirin International, we have a long history of treating bone and mineral diseases, particularly related to metabolic disorders.
Intractable Haematological Diseases and Haemato-Oncology
We strive to develop new treatments and solutions for patients living with diseases and cancers affecting blood and blood-forming organs, bone marrow and related tissues.
Rare Diseases
Rare diseases often go long undiagnosed and overlooked due to the small number of people living with them. At Kyowa Kirin International, however, we are committed to finding novel treatments to better the lives of patients living with rare diseases and make them smile.
Leveraging Innovative Modalities for Drug Discovery and Novel Therapies
We are passionate about using new technologies to develop novel and innovative solutions for some of the world’s rarest diseases.
Advanced Antibody Technology
Kyowa Kirin has a number of high-quality foundational technologies that can be used to efficiently create therapeutic antibodies. We are leveraging our expertise in protein and antibody engineering technologies that we have developed over decades.
In addition, we focus on R&D investment for sustainable growth and to ensure we are bringing more value to patients in need. We are also actively engaged in collaborative research with research institutions to advance next-generation therapeutic antibodies, such as immunostimulatory antibodies and tissue-directed antibodies.
Haematopoietic Stem Cell Gene Therapies
Building on decades of research and advancements in the field of gene therapy, we are working to develop potential cures for genetic and other severe diseases using haematopoietic stem cell gene therapy (HSC-GT).
Our approach harnesses the unique power of a patient’s own genetically modified blood stem cells, also known as haematopoietic stem cells, or HSCs, to potentially correct the underlying cause of a genetic disease permanently using a single administration.
Furthermore, we are also developing new treatments by combining HSC-GT with the drug discovery technologies and expertise that Kyowa Kirin has cultivated over decades.
Supporting Patients
Patients are at the very heart of everything we do. We work to be a voice for patients among all stakeholders, ensuring their needs are heard during all stages of the medicine development continuum. We do this through strong partnerships with key Patient Advocacy Groups (PAGs), and championing disease awareness and treatment approach campaigns to drive best practice for patients.
We are also expanding geographically into Eastern Europe, Africa and Latin America, enabling us to meet the needs of more people across our region.
To find out more about how we are supporting patients, visit our Supporting Patients section here.
ABOUT US | CONTACT US | NOTICES | TERMS OF USE
MODERN SLAVERY ACT | THIRD PARTY CODE OF CONDUCT
KKI/INT/KKI/0920 September 2024
Copyright © Kyowa Kirin International plc. All rights reserved. This website is developed and funded by Kyowa Kirin International plc.
Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.